Introduction
The use of antibiotics in the treatment of infective exacerbations of chronic obstructive airways disease (COAD) is controversial and opinions vary as to which agent should be used for therapy (Anonymous, 1987; Anthonisen et al., 1987; Rodnick & Gude, 1988; van der Meer, 1989; Bannister, 1990; Gross, 1990; Chodosh, 1991; Davies & Jolley, 1992; Dere, 1992) , and even as to whether all patients with exacerbations actually require any antibiotic treatment (Anthonisen et al., 1987) . There is general agreement that patients who are hospitalised with exacerbations of COAD should receive a drug which is active against the two most important pathogens, Haemophilus influenzae and Streptococcus pneumoniae (Anthonisen et al., 1987; Rodnick & Gude, 1988; Bannister, 1990; Gross, 1990; Chodosh, 1991; Dere, 1992) . There is less consensus about the clinical importance of Moraxella catarrhalis, and there is a wide variation in the prevalence of ampiciUin resistant strains of H. influenzae. Consequently, there is controversy regarding the continued use of ampicillin or amoxycillin as first line drugs for hospitalised patients with acute exacerbations of CO AD. New antibiotic protocols, involving amoxycillin as a first line agent, were recently introduced into the regional respiratory unit as part of a series of treatment guidelines aimed at improving and evaluating local prescribing. The purpose of this study was to evaluate the effect of introducing the new antibiotic protocol both in terms of outcome measures of efficacy and cost.
Methods
In February 1991 new antibiotic protocols were introduced. The protocols, based on consensus opinion, recommended the use of amoxycillin (500 mg tid) or erythromycin (500 mg qid, for patients with suspected penicillin allergy) as the first line therapy for exacerbations of COAD, with ciprofloxacin (500 mg bd) reserved for patients who failed to respond. The oral route of administration was recommended, where possible, for all antibiotics. The same antibiotics were to be used even if the patient had already received amoxycillin or erythromycin from their general practitioner (GP) before hospital admission. The rationale for this was that compliance in the community is unlikely to be optimal and that the prescribed dosage is often inadequate. It had previously been agreed, by the respiratory consultants and the microbiology department that sputum samples were not to be collected in cases of infective exacerbations of COAD, unless clinical cure had not been achieved with first or second line antibiotic therapy (Sande, Hudson & Root, 1986) .
At the same time guidelines were also introduced for the treatment of pneumonia which specified the use of the combination of amoxycillin and erythromycin as first line therapy, to be used for the initial treatment of patients with suspected pneumonia on clinical or X-ray diagnosis.
Patients were recruited into the study on admission to a central clearing ward within the respiratory unit. Every third admission from the first November of two sequential years (1990 and 1991) was screened as a potential participant. A total of 140 patients was screened, equally divided between the years. Patients were selected based on the diagnosis given in the discharge letter sent to their GP. Any patient with a discharge diagnosis other than infective exacerbation of COAD was excluded (e.g. patients with pneumonia, bronchiectesis, acute asthmatic attacks or admission for bronchoscopy).
Data were collected retrospectively on a standard form. A modified index of severity was calculated which included both the "respiratory factors" (sputum colour, respiratory function and X-ray findings), and the "non-respiratory factors" (body temperature, white cell count and the medical staffs impression). This severity score had previously been used to identify those cases where antibiotic therapy for respiratory infection was justified, defined as patients with a score of at least two (Moss et al., 1981) . Assessment of response to first line antibiotic treatment was based on the clinical management of patients. Change of antibiotic therapy indicated suspected failure of the initial antibiotic treatment. The decision to change antibiotics was made independently by clinical staff.
Measurement of impact of policy on antibiotic costs
Two methods were used to assess the impact of the prescribing policy on costs. Firstly, the costs of the antibiotics prescribed to the sample of patients were calculated based on the actual price paid for the drugs by the hospital pharmacy. Secondly, the total cost of all antibiotics prescribed in the respiratory unit during the study period was calculated by obtaining pharmacy supply records. Data for each drug were converted to defined daily doses (DDD) (Wessling & Boethius, 1990) , and the cost per DDD was calculated. The mean costs of DDD for all antibiotics were then compared for 1991 and 1992.
Statistical analysis
Students t test for unpaired data was used to compare continuous variables such as length of stay and antibiotic costs, and the Mann-Whitney test was used for ordinal data such as respiratory score. Confidence intervals (95% CI) for means and medians were calculated using MINITAB version 8. The chi-squared test with Yates' correction was used to compare nominal data. Regression analysis was performed using the least squares method.
Results
A total of 86 patients was studied. Table I compares the two groups of patients from 1990 and 1991. There were no statistically significant differences between the groups with respect to age, sex or pre-treatment by the GP. Amoxycillin was the most commonly prescribed antibiotic by GPs and accounted for 13/35 (37-1%) of pre-admission prescriptions (Figure 1 ). Figure 2 shows that patients in 1990 tended to have lower severity scores. The median score in 1990 was 3 (95% CI 2-5-3-5; range 0-7) while in 1991 it was 4 (95% CI 3-5-4-5; range 1-8; P < 0005). The proportion of patients with scores of <2 was 19/44 (43-2%) in 1990 vs 7/42 (16-7%) in 1991 (5-96, P < 002). The data recorded by the admitting physician were of similar quality in the two study periods, with the majority of the factors required to calculate the severity score being recorded.
The proportion of patients who responded to the first antibiotic prescribed was similar (68% in 1990 vs 67% in 1991). There was no statistically significant difference between Table I the two years in terms of patient length of stay or duration of antibiotic treatment (Table II) . The impact of the guidelines on the range of antibiotics used was assessed by comparing the total number of treatment days prescribed for each drug. Following the introduction of the guidelines, there was a marked increase in the use of amoxycillin, from 18% to 56% of the total treatment days, and small decreases in the overall use of erythromycin (from 23% to 15%) and ciprofloxacin (from 28% to 21%). There were marked decreases in the use of co-amoxiclav (from 9% to 02%) and other antibiotics not recommended in the treatment guidelines (from 22% to 8%). Compliance with the policy was high with over 81% of all first line prescriptions for either amoxycillin or erythromycin. A further 15% of patients were diagnosed by the junior staff as having a pneumonia, and therefore prescribed combination therapy of amoxycillin and erythromycin, but were subsequently given a discharge diagnosis of infective exacerbation of COAD at which point therapy was altered to a single agent. The distribution of antibiotic costs for study patients was highly skewed. In 1990 the mean cost per patient was £1409, the median was £3-30 and the range £0-60-115-11. In 1991 the corresponding figures were £10-20, £1-75, and £0-30-20-97 . Because of the skewed distribution, the data were analysed with the Mann-Whitney test. The median cost per patient and the median cost per day of treatment were both significantly lower in 1991 than in 1990 (Table II) . The average cost per DDD of all antibiotics prescribed in the respiratory unit also fell from £3-77 in 1990 to £1-71 in 1991 (average reduction 54-6%, 95% CI 52-3-56-9%, P < 0-05).
Patients who responded to first line therapy were treated on average for 7 fewer days in 1990 and 5-4 fewer days in 1991 than those patients who did not respond to the antibiotic of first choice (Table III) . Similarly the length of stay was shorter in patients who responded to first line therapy, by an average of 8-7 days in 1990 and 3-8 days in 1991 (Table III) . There was no obvious relationship between the respiratory severity score and either length of antibiotic treatment or length of stay. There was no significant difference in response to first line therapy in the patients who had compared with those who had not been treated by their GP. However, there was a trend towards a lower response rate in patients who had received antibiotics (21/35, 60% vs 35/47, 75%, P > 0-1). Mean length of stay (95% CI): (days) responded to first line treatment did not respond to first line treatment P (unpaired t test) 7-6 (5-8 to 9-4) 14-6(10-4 to 18-8) <005
91 (7-3 to 10-9) 17-8 (10-6 to 250) <005 7-3(5-1 to 9-5) 12-7(10-3 to 151) <005
8-7 (6-5 to 109) 12-5 (6 9 to 181) <005
Discussion
The measurement of clinical outcome is desirable in audit (Frater & Costain, 1992) . The outcome parameters used in the present study were the duration of stay in hospital, the total length of antibiotic treatment and the clinical response to first line antibiotic therapy. The cost of antibiotics prescribed was also used as a measure of the effectiveness of the protocols, although cost reduction was not the primary aim of the introduction of the guidelines. The primary aim of the audit was to improve antibiotic prescribing within a respiratory unit comprising four wards with four consultants and rotating junior staff. In this respect the introduction of the policy did meet the primary objective. The outcome data were relatively easily obtained from patients' case records and the pharmacy computer system. Data from the two years must be interpreted with some caution as other factors such as co-existing diseases and social factors may contribute to length of stay and length of antibiotic therapy. A respiratory infection severity score was used to gain some indication of the patients' requirement for antibiotic therapy. In a study by Moss et al. (1981) antibiotic therapy was justified in any patient with a severity score greater than 2. By these criteria the majority of our patients required antibiotic therapy. The index of severity showed no significant correlation with length of stay or duration of treatment and cannot therefore be used to predict these outcomes. A larger prospective study would be required to identify risk factors which do predict either response to antibiotic treatment or length of stay. Proving that failure of antibiotic treatment directly causes increased length of stay requires a randomised controlled trial of treatments with different response rates.
Although there was no statistically significant difference in response rate in those patients who were pre-treated by their GP compared with those who were not given antibiotics, there was a tendency for the latter to respond better to first line therapy. Hence, there may come a point when it will be more cost-effective for those treated by their GP to follow a different protocol. In our study we found a first line response rate of 62% which is similar to that observed for oral amoxycillin in a previous comparative trial (Basran et al., 1990) . It is appreciated that clinical cure is only one method of assessing the outcome of treatment and that other indices may be used including sputum culture. The practice in the study unit is that sputum samples are not routinely collected and therefore the only consistently measurable outcome in the patients included in the study was clinical cure.
In conclusion, the introduction of prescribing guidelines, which specified relatively common and inexpensive antibiotics for the treatment of exacerbations of CO AD, had no detrimental effect on outcome and reduced drug therapy costs. However, the overall clinical response rate to first line therapy (67%) clearly leaves considerable scope for improvement. Given the association between non-response and length of stay, drugs such as ciprofloxacin might prove to be more cost-effective than amoxycillin (Basran et al., 1990) . The audit we have established in this study provides a system for evaluating future proposed changes to the antibiotic guidelines. The next logical step would therefore be a prospective, double-blind comparison of amoxycillin with ciprofloxacin, the current second line treatment.
